However, larger and well-controlled clinical trials are needed to evaluate the efficacy and safety of DRD2 agonists, like pramipexole, in diverse sepsis patient populations, considering factors like sepsis stage, infection source, and comorbidities. This evidence concerns the gene DRD2 and Sepsis.